Flex Biomedical
Flex Biomedical: U.S. provider of biotech products and services for orthopedic treatment.
Founded
2007Flex Biomedical: U.S. provider of biotech products and services for orthopedic treatment.
Founded in 2007, Flex Biomedical is dedicated to developing innovative treatments and diagnostics for orthopedic injuries and diseases. The company's core mission is to provide solutions that help manage pain and delay the need for joint replacement, particularly for those suffering from osteoarthritis. Their flagship product, Flex Polymer™, is an injectable synthetic polymer designed to offer enhanced cushioning and lubrication within joints, providing longer-lasting pain relief and slowing the progression of osteoarthritis. Flex Biomedical primarily serves the U.S. market.
Notable individuals affiliated with Flex Biomedical include key researchers and industry experts in biotechnology and orthopedics. The company has attracted investment from prominent venture capital firms specializing in healthcare innovation. Among its key achievements, Flex Biomedical has made significant strides in clinical trials demonstrating the efficacy of Flex Polymer™, contributing to improved quality of life for patients with joint issues. The overall impact of Flex Biomedical lies in its potential to transform orthopedic care by offering non-surgical treatment options that address a critical need in pain management and joint health.
Companies similar to Flex Biomedical include Biomimedica, Sparta Biomedical, Glycologix and Hyalex Orthopaedics.
Flex Biomedical was founded in 2007.
Flex Biomedical's headquarters is located in Madison, WI, US.
Flex Biomedical's most recent funding round was for $150k (USD) in May 2014.
As of May 7, 2014, Flex Biomedical has raised a total of $4.4M (USD).
Flex Biomedical has 6 employees as of Feb 5, 2024.
Glycologix
glycologix.com
